Genfit - ADR
GNFT
Get informed when a big investor buys or sells
+ FollowMarket Cap$789.02M
Close$
$-4.84
154.1% downside
Current Fair Value
154.1% downsideOvervalued by 154.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $789.02 Million |
|---|---|
| Enterprise Value | $854.47 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.03 |
| Beta | 0.87 |
| Outstanding Shares | 49,780,000 |
Return
| Return on Equity | 284.57% |
|---|---|
| Return on Assets | -91.75% |
| Return on Invested Capital | -146.36% |
Valuation & Multiples
| P/E Ratio | -4.06 |
|---|---|
| PEG | -2.5 |
| Price to Sales | 8.95 |
| Price to Book Ratio | -8.95 |
| Enterprise Value to Revenue | 8.85 |
| Enterprise Value to EBIT | -9.08 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.21 |
| Debt to Equity | -3.62 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
April 22, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 0.09% |
|---|---|
| Total Invested | $30▼ 99.98% |
| Investors Holding | 1▼ 5.00% |
ESG Score
No data
About Genfit
130 employees
CEO: Pascal Prigent Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in...